Regeneron Pharmaceuticals (STU:RGO) E10: €32.00 (As of Mar. 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
87 GF Score
Price €551.80
GF Value €785.39
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals E10?

Regeneron Pharmaceuticals STU:RGO -0.50% 87 E10 is €32.00 as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 87/100 and a GF Value™ of €785.39 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was €5.839. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €32.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Regeneron Pharmaceuticals's average E10 Growth Rate was 13.30% per year. During the past 3 years, the average E10 Growth Rate was 14.90% per year. During the past 5 years, the average E10 Growth Rate was 24.10% per year. During the past 10 years, the average E10 Growth Rate was 43.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Regeneron Pharmaceuticals was 156.60% per year. The lowest was -9.00% per year. And the median was 14.90% per year.

As of today (2026-06-30), Regeneron Pharmaceuticals's current stock price is €551.80. Regeneron Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was €32.00. Regeneron Pharmaceuticals's Shiller PE Ratio of today is 17.24.

During the past 13 years, the highest Shiller PE Ratio of Regeneron Pharmaceuticals was 308.06. The lowest was 15.01. And the median was 40.97.


Regeneron Pharmaceuticals  (STU:RGO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regeneron Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=551.80/32.00
=17.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Regeneron Pharmaceuticals was 308.06. The lowest was 15.01. And the median was 40.97.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Regeneron Pharmaceuticals E10 Related Terms


Regeneron Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals E10 Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.43 21.93 24.66 30.07 30.64

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.15 28.69 30.08 30.64 32.00

STU:RGO vs ALNY, RVMD, ONC: E10 Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Shiller PE Ratio falls into.


STU:RGO
87GF Score
Regeneron Pharmaceuticals Inc STU:RGO
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5.839/330.2130*330.2130
=5.839

Current CPI (Mar. 2026) = 330.2130.

Regeneron Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 1.504 241.018 2.061
201609 2.023 241.428 2.767
201612 2.076 241.432 2.839
201703 2.020 243.801 2.736
201706 2.973 244.955 4.008
201709 2.785 246.819 3.726
201712 1.267 246.524 1.697
201803 3.374 249.554 4.465
201806 4.126 251.989 5.407
201809 4.431 252.439 5.796
201812 6.285 251.233 8.261
201903 3.531 254.202 4.587
201906 1.487 256.143 1.917
201909 5.321 256.759 6.843
201912 6.237 256.974 8.015
202003 4.914 258.115 6.287
202006 6.758 257.797 8.656
202009 6.274 260.280 7.960
202012 8.417 260.474 10.671
202103 8.476 264.877 10.567
202106 23.215 271.696 28.215
202109 12.181 274.310 14.663
202112 17.426 278.802 20.639
202203 7.818 287.504 8.979
202206 7.067 296.311 7.876
202209 11.777 296.808 13.102
202212 9.912 296.797 11.028
202303 6.697 301.836 7.327
202306 7.846 305.109 8.492
202309 8.330 307.789 8.937
202312 9.344 306.746 10.059
202403 5.768 312.332 6.098
202406 11.529 314.175 12.118
202409 10.398 315.301 10.890
202412 7.697 315.605 8.053
202503 6.725 319.799 6.944
202506 11.106 322.561 11.369
202509 11.604 324.800 11.797
202512 6.712 324.054 6.840
202603 5.839 330.213 5.839

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €32.00 mean?
Regeneron Pharmaceuticals (STU:RGO) has a E10 of €32.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' E10 too high?
Regeneron Pharmaceuticals' current E10 is €32.00. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' E10 compare to ALNY and RVMD?
Regeneron Pharmaceuticals' E10 of €32.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current E10 is €32.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Significantly Undervalued. The stock's GF Value™ is €785.39, compared to a current price of €551.80 — trading 29.7% below its estimated fair value. The current E10 is €32.00. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current E10 is €32.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €551.80 is trading 29.7% below its estimated GF Value™ of €785.39. GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:RGO:

  • E10: €32.00
  • GF Value™: €785.39 vs. price of €551.80 (29.7% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for STU:RGO

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€551.80
Price
€785.39
GF Value